Cellectis S.A.
CLLSNasdaqCIK 1627281HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: Q4 FY2023
Three months to Dec 31, 2023, against the same quarter a year earlier.
- Revenuenot reported (Revenue not reported)No year-earlier figure to compare
- Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue not reported)No year-earlier figure to compare
- Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
- Free cash flownot reported (Operating cash flow and Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | period not labelled2023-06-30 | period not labelled2023-09-30 | Q4 FY20232023-12-31 | Shape over the periods |
|---|---|---|---|---|---|
| Revenue | $ | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | |
| Operating margin | % | not reported (Operating income and Revenue not reported) | not reported (Operating income and Revenue not reported) | not reported (Revenue not reported) | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | |
| Diluted EPS | $ per share | (0.20)Diluted EPS, period not labelled, three months to 2023-06-30−$0.20 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-04-29, accession 0000950170-24-050016.Report this figure | not reported (Diluted EPS not reported) | not reported (Diluted EPS not reported) | |
| Free cash flow | $ | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) | not reported (Operating cash flow and Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | 30.3Revenue, FY2021, twelve months to 2021-12-31$30.3m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-04-29, accession 0000950170-24-050016.Report this figure | 19.2Revenue, FY2022, twelve months to 2022-12-31$19.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-14, accession 0000950170-25-039038.Report this figure | 0.8Revenue, FY2023, twelve months to 2023-12-31$755.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | 41.5Revenue, FY2024, twelve months to 2024-12-31$41.5m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | 72.9Revenue, FY2025, twelve months to 2025-12-31$72.9m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | (341.0%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$103.5m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-04-29, accession 0000950170-24-050016.Revenue: $30.3m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-04-29, accession 0000950170-24-050016.Report this figure | (467.7%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$89.7m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-03-14, accession 0000950170-25-039038.Revenue: $19.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-14, accession 0000950170-25-039038.Report this figure | (12887.7%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$97.3m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Revenue: $755.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | (143.5%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$59.6m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Revenue: $41.5m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | (45.3%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$33.1m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Revenue: $72.9m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | |
| Net margin | % | (376.3%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$114.2m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2024-04-29, accession 0000950170-24-050016.Revenue: $30.3m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-04-29, accession 0000950170-24-050016.Report this figure | (553.6%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$106.1m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-03-14, accession 0000950170-25-039038.Revenue: $19.2m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-03-14, accession 0000950170-25-039038.Report this figure | (13385.3%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$101.1m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-20, accession 0001193125-26-116428.Revenue: $755.0k. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | (88.6%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$36.8m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-20, accession 0001193125-26-116428.Revenue: $41.5m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | (92.7%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$67.6m. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2026-03-20, accession 0001193125-26-116428.Revenue: $72.9m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | |
| Diluted EPS | $ per share | (2.55)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.55 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-04-29, accession 0000950170-24-050016.Report this figure | (2.33)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.33 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-03-14, accession 0000950170-25-039038.Report this figure | (1.77)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.77 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | (0.41)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.41 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | (0.67)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.67 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | |
| Free cash flow | $m | (123)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$104.6m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-04-29, accession 0000950170-24-050016.Capital expenditure: $18.5m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-04-29, accession 0000950170-24-050016.Report this figure | (89.9)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$87.4m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-03-14, accession 0000950170-25-039038.Capital expenditure: $2.4m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-03-14, accession 0000950170-25-039038.Report this figure | (25.8)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$24.7m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Capital expenditure: $1.1m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | 20.4Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $23.0m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Capital expenditure: $2.6m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure | (41.8)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$39.4m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Capital expenditure: $2.4m. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-03-20, accession 0001193125-26-116428.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| B Group, Inc. | 2026-06-30 | $9.8m | 3,281,501 | Unchanged | |
| Long Focus Capital Management, LLC | 2026-06-30 | $8.2m | 2,741,853 | Reduced−2,245 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2026-06-30 | $7.9m | 2,644,881 | Reduced−533,739 | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2026-06-30 | $681.0k | 226,875 | Unchanged | |
| BlackRock, Inc. | 2026-06-30 | $676.3k | 225,444 | Reduced−116,079 | |
| MORGAN STANLEY | 2026-06-30 | $256.4k | 85,455 | Reduced−1,321 | |
| LPL Financial LLC | 2026-06-30 | $253.2k | 84,415 | Added+70 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-06-30 | $151.4k | 50,453 | Reduced−15,489 | |
| BNP PARIBAS FINANCIAL MARKETS | 2026-06-30 | $120.3k | 40,100 | Reduced−900 | |
| UBS Group AG | 2026-06-30 | $101.8k | 33,926 | Added+4,152 |
Recent filings
All 528 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2806:00 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-27 | 0001171843-26-006873 |
| 2026-09-1406:00 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-14 | 0001171843-26-006010 |
| 2026-09-1116:35 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-11 | 0001171843-26-006002 |
| 2026-09-0116:35 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-01 | 0001171843-26-005837 |
| 2026-08-0616:35 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-06 | 0001171843-26-005324 |
| 2026-08-0616:30 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-06 | 0001193125-26-338220 |
| 2026-07-3016:35 ET | 6-K | Report of a foreign private issuerPeriod 2026-07-30 | 0001171843-26-005091 |
| 2026-06-2516:35 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-25 | 0001171843-26-004304 |
| 2026-06-2516:30 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-25 | 0001193125-26-282865 |
| 2026-06-1107:00 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-11 | 0001171843-26-004051 |
Latest annual report
Form 20-F for the fiscal year ended Dec 31, 2025Filed Mar 20, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1627281
- Tickers
- CLLS
- Exchange
- Nasdaq
- SIC code
- 2836 Biological Products, (No Diagnostic Substances)
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- I0
- Filer category
- Accelerated filer
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 06:05 ET. Listed shows no prices and gives no investment advice.